Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.

导出 OA

翻译打印收藏纠错

第一作者： Tetsuhide,Ito

第一单位： Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Fukuoka Higashi-ku, Fukuoka, Japan. itopapa@med.kyushu-u.ac.jp.

作者： Tetsuhide,Ito ^[1] ; Yoshitaka,Honma ^[2] ; Susumu,Hijioka ^[3] ; Atsushi,Kudo ^[4] ; Akira,Fukutomi ^[5] ; Akira,Nozaki ^[6] ; Yasutoshi,Kimura ^[7] ; Fuyuhiko,Motoi ^[8] ; Hiroyuki,Isayama ^[9] ; Izumi,Komoto ^[10] ; Seiichi,Hisamatsu ^[11] ; Akihiro,Nakajima ^[11] ; Akira,Shimatsu ^[12]

作者单位： Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Fukuoka Higashi-ku, Fukuoka, Japan. itopapa@med.kyushu-u.ac.jp. ^[1] Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan. ^[2] Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan. ^[3] Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan. ^[4] Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. ^[5] Department of Medical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. ^[6] Department of Surgery, Surgical Oncology and Science, Sapporo Medical University Hospital, Sapporo, Japan. ^[7] Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan. ^[8] Gastroenterology, The University of Tokyo Hospital, Tokyo, Japan. ^[9] Department of Surgery, Kansai Electric Power Hospital, Osaka, Japan. ^[10] Pharmaceutical Research & Development Division, Teijin Pharma Limited, Tokyo, Japan. ^[11] Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan. ^[12]

关键词 Japanese Lanreotide Neuroendocrine tumor Phase II Somatostatin analog